Alzheimer's Disease is Incurable but Preventable
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The dramatic rising incidence and costs of Alzheimer's disease (AD) require that research efforts and funding be primarily directed on either finding a cure or applying preventive measures to curb this disorder. A cure for AD appears unlikely when significant cognitive loss has occurred because the neuronal networks that controlled the perturbed cognitive abilities are either dead or irreversibly damaged and replacing them, even if it were technically possible, would not reconstruct the intellectual identity of the host. Prevention of risk factors to sporadic AD is a more realistic stratagem and treatment, when indicated, ideally should begin in cognitively intact individuals as part of a mass screening effort. Prevention of modifiable risk factors to AD is cost-effective because it reduces hospice or hospital stay, repeated doctor visits, and long-term care. Presently, neurocognitive and neuroimaging tests are used with partial success in identifying persons at higher risk of AD but these tests can not pinpoint either a cause or a specific intervention that could attenuate disease progress. We previously proposed that carotid artery ultrasound +echocardiography together with ankle-brachail index (CAUSE+ABI) as mass screening tests in asymptomatic persons could detect not only cardio-cerebrovascular risk factors to AD, but also identify an indicated intervention. CAUSE+ABI are simple to perform, cost-effective, non-invasive, and reasonably accurate for the intended purpose. Additionally, detection of cardio-cerebrovasacular abnormalities long before expression of cognitive deterioration allows higher success rate with earlier treatment. Evidence-based medicine is recommended for optimizing clinical decision-making in evaluating AD risk factors and their treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 2×
“Neuropathologically, the mildest form of this stage (CDR = 0.5), already shows a 60% and 40% loss of neurons in the entorhinal cortex lamina II and lamina IV, respectively, as compared to cognitively normal controls [20].”
InfluentialAn Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681 · cited 1×
“Ways of reporting results from clinical trials can be expressed as the reduction in absolute relative risk and in the number of people who need to be treated to prevent one adverse event, which is the equivalent of the reciprocal of the absolute risk reduction [54].”
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 2×
“1 are influential in the preclinical development of AD [24–28].”
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 2×
“Epidemiological studies have reported over two dozen risk factors for AD, most of which are vascular-related [24–28 , 32] and modifiable.”
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118 · cited 1×
“This conclusion is supported by evidence that high Aβ deposits in AD are not associated with brain atrophy, brain cell loss, or cognitive decline [9,10].”
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664 · cited 2×
“1 are influential in the preclinical development of AD [24–28].”
Clare, L., & Woods, B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003260 · Cited by 576 · cited 1×
“…worthyclinical goals but so far, meta-analyses of drug trials and rehabilitation programs of AD patients shows no statistical signifi-cance for improvement of cognitive function using any pharmacological intervention or cognitive training in-terventionsfor people with AD or vascular dementia [4, 5].”
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Promising Strategies for the Prevention of Dementia
Middleton, L. E., & Yaffe, K. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.201 · Cited by 396 · cited 1×
“By contrast, all these treatments have also been re-ported to have positive clinical effects in limiting cognitive deterioration and should not be dismissed until further evidence reveals their relative merit in preventing cognitiveimpairment [23,42].”
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · cited 1×
“Examples of some treatments that lack consistent evidence for their use in the prevention of cognitive decline are statins [37], carotid endarterectomy [38], anti-hypertensive medication [39], folic acid [40], and vitamin E [41].”
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b59bf3 · Cited by 232
Cited by
The relationship between obesity and cognitive health and decline
Dye, L., Boyle, N. B., Champ, C., & Lawton, C. (2017) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117002014 · Cited by 469
“At present, neuroscientists working in the field of AD indicate strong doubts that a cure will be found soon((7)).”
BackgroundCardiovascular Risk Factors Promote Brain Hypoperfusion Leading to Cognitive Decline and Dementia
de la Torre, J. C. (2012) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2012/367516 · Cited by 440
Self-citationDiet and Alzheimer’s disease risk factors or prevention: the current evidence
Solfrizzi, V., Panza, F., Frisardi, V., Seripa, D., Logroscino, G., Imbimbo, B. P., & Pilotto, A. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.56 · Cited by 297
Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration
Balestrini, S., Perozzi, C., Altamura, C., Vernieri, F., Luzzi, S., Bartolini, M., Provinciali, L., & Silvestrini, M. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d71a · Cited by 126
Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease
Adalier, N., & Parker, H. (2016) · Antioxidants · doi:10.3390/antiox5040040 · Cited by 40
Metadata
- Authors
- de la Torre, J. C.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-05-26
- Volume
- 20
- Issue
- 3
- Pages
- 861-870
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1666633781
- Cited by
- 123
- References
- 13
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.